How to help manage patients successfully on their two-year treatment with Verzenio and ET

Our expert speakers will be discussing the recent data for Verzenio & ET, and share their experiences in managing high risk EBC patients during their adjuvant journey

^{*high risk EBC was defined as patients who had 1–3 positive nodes with either grade 3, tumour size ≥ 5cm or a Ki-67 ≥ 20%, or who had ≥ 4 positive nodes1

1. Johnston S, et al Ann Oncol. 2025 Oct 17:S0923-7534(25)04948-8.

CMAT-22763. April 2026. This meeting has been developed, organised and funded by Eli Lilly & Company.}

INDUSTRY BREAKFAST | Overall Survival and why it matters in high-risk* HR+ HER2- Early Breast Cancer

Session sponsor